ArticleWorld journal of gastroenterology2025
Beyond the skin - metastatic basal cell carcinoma in the stomach: A case report.
Article in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBasal cell carcinoma (BCC) is the most prevalent skin cancer, characterized by indolent growth and low metastatic rates. When metastatic BCC (mBCC) does occur, it most commonly involves lymph nodes, lungs, and bones, with metastases to other sites being exceptionally rare. This case reports the first documented instance of mBCC to the stomach, highlighting the importance of considering atypical metastatic sites, and the challenges associated with diagnosis and management. CASE SUMMARY: A 52-year-old male with recurrent BCC and known mBCC to the bone presented with progressive dysphagia, cranial neuropathies and generalized weakness. He had been treated with immune checkpoint inhibitors, with intermittent therapy modifications due to treatment related toxicities. His past history was notable for malignant perineural invasion, radiotherapy for osseous metastases, immune checkpoint inhibitor-induced enteritis, and osteonecrosis of the jaw. Gastroscopy revealed subepithelial gastric lesions, and biopsies confirmed mBCC - a previously unreported site of disease dissemination. A multidisciplinary team involving gastroenterology, oncology, neurology, and palliative care guided his management. Given his declining functional status and poor prognosis, he was ultimately transitioned to hospice care.
conclusionClinicians should consider atypical metastatic sites in advanced BCC. A multidisciplinary approach remains essential for timely diagnosis and coordinated management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.